Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Viscoli, C. M.    Singer, B. H.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

ß-Blockers after Myocardial Infarction: Influence of First-Year Clinical Course on Long-Term Effectiveness

Catherine M. Viscoli; Ralph I. Horwitz; and Burton H. Singer

15 January 1993 | Volume 118 Issue 2 | Pages 99-105

Objective: To develop a strategy for evaluating drug efficacy over time that accounts for heterogeneous clinical courses evolving after initiation of therapy and to demonstrate its use in assessing the long-term therapeutic benefit of propranolol after myocardial infarction.

Design: Analysis of data from the Beta-Blocker in Heart Attack Trial (BHAT), a randomized, double-blind, placebo-controlled trial that enrolled patients from 1978 to 1980 and followed participants for vital status to April 1982.

Setting: Thirty-one clinical centers in the United States and Canada.

Patients: Eligible patients included 3297 men and women 30 to 69 years of age who survived 1 year after trial entry.

Intervention: Patients were classified as being on treatment at 12 months after randomization if they were receiving ß-blocker therapy at the 12-month visit and off treatment if they were not receiving ß-blocker therapy at that time.

Outcome Measure: Vital status evaluated at 720 days of follow-up.

Results: A total of 2914 patients (88%) was classified as being at lower risk (strata I and II). For these patients, survival curves by treatment at 12 months were virtually indistinguishable. Among the 383 patients categorized as being at high risk on the basis of recurrent ischemic events, arrhythmias, congestive heart failure, or severe comorbidity during the first 12 months, the use of ß-blockers was associated with a 43% proportional decline in the subsequent risk for death (P = 0.01 by log-rank test).

Conclusions: In patients who survived to 1 year with low- to moderate-risk clinical courses, ß-blocker therapy did not have long-term beneficial effect. In contrast, among patients who had a high-risk clinical course during the first year, ß-blockers significantly reduced mortality in the follow-up period.

Author and Article Information

From Yale University School of Medicine, New Haven, Connecticut.
Requests for Reprints: Ralph I. Horwitz, MD, Yale University School of Medicine, Room IE-61, SHM, P.O. Box 3333, New Haven, CT 06510.
Acknowledgments: The authors thank the BHAT investigators, particularly the project director, Robert Byington, for providing access to the trial data.
Grant Support: In part by U.S. Public Health Service training grant 5-T32-HL07428 (Dr. Viscoli).

This article has been cited by other articles:

				S. K. Inouye, Y. Zhang, R. N. Jones, D. K. Kiely, F. Yang, and E. R. Marcantonio Risk Factors for Delirium at Discharge: Development and Validation of a Predictive Model Arch Intern Med, July 9, 2007; 167(13): 1406 - 1413. [Abstract] [Full Text] [PDF]

				A. D. Federman, A. S. Adams, D. Ross-Degnan, S. B. Soumerai, and J. Z. Ayanian Supplemental Insurance and Use of Effective Cardiovascular Drugs Among Elderly Medicare Beneficiaries With Coronary Heart Disease JAMA, October 10, 2001; 286(14): 1732 - 1739. [Abstract] [Full Text] [PDF]

				S. C. Smith Jr, S. N. Blair, R. O. Bonow, L. M. Brass, M. D. Cerqueira, K. Dracup, V. Fuster, A. Gotto, S. M. Grundy, N. H. Miller, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update: A Statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology Circulation, September 25, 2001; 104(13): 1577 - 1579. [Full Text] [PDF]

				S. C. Gan, S. K. Beaver, P. M. Houck, R. F. MacLehose, H. W. Lawson, and L. Chan Treatment of Acute Myocardial Infarction and 30-Day Mortality among Women and Men N. Engl. J. Med., July 6, 2000; 343(1): 8 - 15. [Abstract] [Full Text] [PDF]

				T Laperche, D Logeart, A Cohen-Solal, and R Gourgon Potential interests of heart rate lowering drugs Heart, April 1, 1999; 81(4): 336 - 341. [Full Text]

				K S Spargias, A S Hall, D C Greenwood, and S G Ball beta Blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study Heart, January 1, 1999; 81(1): 25 - 32. [Abstract] [Full Text]

				S. K. Inouye, P. N. Peduzzi, J. T. Robison, J. S. Hughes, R. I. Horwitz, and J. Concato Importance of Functional Measures in Predicting Mortality Among Older Hospitalized Patients JAMA, April 15, 1998; 279(15): 1187 - 1193. [Abstract] [Full Text] [PDF]

				J. P. A. Ioannidis, J. C. Cappelleri, and J. Lau Issues in Comparisons Between Meta-analyses and Large Trials JAMA, April 8, 1998; 279(14): 1089 - 1093. [Abstract] [Full Text] [PDF]

				G. Chatellier, E. Zapletal, D. Lemaitre, J. Menard, and P. Degoulet The number needed to treat: a clinically useful nomogram in its proper context BMJ, February 17, 1996; 312(7028): 426 - 429. [Full Text]

				WHEN TO STOP BETA-BLOCKERS AFTER MI Journal Watch (General), January 22, 1993; 1993(122): 2 - 2. [Full Text]